HBM Holdings Limited (HBMHF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HBM Holdings Limited (HBMHF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 53/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026HBM Holdings Limited (HBMHF) Gesundheitswesen & Pipeline-Uebersicht
HBM Holdings Limited is a clinical-stage biopharmaceutical company specializing in differentiated antibody therapeutics for immunology and oncology, operating in Mainland China, the United States, Europe, and internationally, with a focus on developing treatments for autoimmune diseases, cancers, and viral infections, reflected in its high gross and profit margins.
Investmentthese
HBM Holdings Limited presents an investment opportunity in the clinical-stage biopharmaceutical sector, driven by its diverse pipeline of antibody therapeutics targeting significant unmet needs in immunology and oncology. The company's high gross margin of 91.2% and profit margin of 57.2% indicate efficient operations and strong potential for profitability upon successful commercialization of its drug candidates. Key value drivers include the clinical progress of Batoclimab and Tanfanercept, with potential catalysts being positive clinical trial results and regulatory approvals. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's beta of 1.71 suggests higher volatility compared to the market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $1.30 billion reflects investor valuation of HBM Holdings' pipeline and potential.
- P/E ratio of 32.26 indicates the price investors are willing to pay for each dollar of HBM Holdings' earnings.
- Profit margin of 57.2% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 91.2% signifies the efficiency of HBM Holdings' operations in developing its therapeutics.
- Beta of 1.71 suggests that the stock is more volatile than the market, potentially offering higher returns but also greater risk.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diverse pipeline of antibody therapeutics.
- Strategic collaborations with established companies.
- High gross and profit margins.
- Experienced management team.
Schwaechen
- Clinical-stage company with no approved products.
- Reliance on clinical trial outcomes.
- High research and development expenses.
- Dependence on partnerships for certain programs.
Katalysatoren
- Upcoming: Clinical trial results for Batoclimab (HBM9161) in autoimmune diseases.
- Upcoming: Clinical trial results for Tanfanercept (HBM9036) in dry eye disease.
- Upcoming: Regulatory submissions for key pipeline assets.
- Ongoing: Advancement of oncology pipeline, including HBM7008 and HBM4003.
- Ongoing: Strategic collaborations and partnerships.
Risiken
- Potential: Clinical trial failures for pipeline assets.
- Potential: Regulatory delays or rejections.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: High research and development expenses.
- Ongoing: Intellectual property challenges.
Wachstumschancen
- Batoclimab (HBM9161) development for autoimmune diseases represents a significant growth opportunity. The autoimmune disease market is projected to reach $153.27 billion by 2030. Positive clinical trial results and regulatory approvals could drive substantial revenue growth for HBM Holdings. The company aims to address unmet needs in this area with its novel antibody therapeutic.
- Tanfanercept (HBM9036) for dry eye disease offers another growth avenue. The dry eye disease market is expected to reach $7.5 billion by 2028. Successful clinical development and commercialization of Tanfanercept could capture a significant share of this market. HBM Holdings is targeting a large patient population with this therapeutic.
- Expansion of the oncology pipeline, including HBM7008 and HBM4003, presents a long-term growth opportunity. The global oncology market is projected to reach $536.01 billion by 2030. Advancing these candidates through clinical trials and securing regulatory approvals could significantly enhance HBM Holdings' market position. The company is focused on developing innovative therapies for various cancer types.
- Strategic collaborations with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. on antibody-drug conjugate (ADC) projects can accelerate drug development and expand HBM Holdings' therapeutic capabilities. The ADC market is expected to grow substantially in the coming years. These partnerships provide access to advanced technologies and expertise, enhancing the company's competitive advantage.
- Geographic expansion into new markets, particularly in Europe and Asia, offers additional growth potential. HBM Holdings currently operates in Mainland China, the United States, and Europe. Expanding its commercial footprint into new regions can drive revenue growth and increase market share. The company is exploring opportunities to commercialize its products in additional territories.
Chancen
- Successful clinical development and commercialization of pipeline assets.
- Expansion into new therapeutic areas.
- Geographic expansion into new markets.
- Further strategic collaborations and partnerships.
Risiken
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Intellectual property challenges.
Wettbewerbsvorteile
- Proprietary antibody therapeutics platform.
- Strong intellectual property portfolio.
- Strategic collaborations with leading biotechnology companies.
- Experienced management team with expertise in drug development.
- Focus on unmet medical needs in immunology and oncology.
Ueber HBMHF
HBM Holdings Limited, established in 2016 and headquartered in Shanghai, China, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative antibody therapeutics. The company focuses on addressing unmet medical needs in immunology and oncology. HBM Holdings' pipeline includes Batoclimab (HBM9161), a human monoclonal antibody targeting the neonatal fragment crystallizable receptor, aimed at treating autoimmune diseases. Tanfanercept (HBM9036) is being developed for moderate-to-severe dry eye disease. Additionally, the company is advancing HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. Further pipeline assets include HBM9022 for SARS-COV-2, HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and several other candidates targeting solid tumors. HBM Holdings operates across Mainland China, the United States, Europe, and internationally. The company collaborates with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. on antibody-drug conjugate projects, expanding its therapeutic capabilities.
Was das Unternehmen tut
- Discovers and develops antibody therapeutics.
- Focuses on immunology and oncology disease areas.
- Develops Batoclimab (HBM9161) for autoimmune diseases.
- Develops Tanfanercept (HBM9036) for dry eye disease.
- Develops HBM7008, a bispecific antibody targeting tumor-associated antigens.
- Develops HBM4003, a human anti-CTLA-4 antibody.
- Develops HBM9022 for the treatment of SARS-COV-2.
- Collaborates on antibody-drug conjugate projects.
Geschaeftsmodell
- Develops and patents novel antibody therapeutics.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals for commercialization.
- Partners with other companies for development and commercialization.
- Generates revenue through product sales and licensing agreements.
Branchenkontext
HBM Holdings operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The industry is driven by increasing demand for innovative therapies, particularly in oncology and immunology. The competitive landscape includes established pharmaceutical companies and other emerging biotech firms. HBM Holdings differentiates itself through its focus on differentiated antibody therapeutics and strategic collaborations. The global biotechnology market is projected to reach significant growth in the coming years, driven by advancements in drug discovery and personalized medicine.
Wichtige Kunden
- Patients suffering from autoimmune diseases.
- Patients with moderate-to-severe dry eye disease.
- Patients diagnosed with various types of cancer.
- Healthcare providers and hospitals.
- Pharmaceutical companies through partnerships and licensing.
Finanzdaten
Chart & Info
HBM Holdings Limited (HBMHF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer HBMHF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer HBMHF.
Kursziele
Wall-Street-Kurszielanalyse fuer HBMHF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von HBMHF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Jingsong Wang
CEO
Jingsong Wang is the CEO of HBM Holdings Limited. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions in various pharmaceutical companies, contributing to the advancement of innovative therapies. His expertise spans across multiple therapeutic areas, including oncology and immunology. He is responsible for overseeing the strategic direction and operations of HBM Holdings.
Erfolgsbilanz: Under Jingsong Wang's leadership, HBM Holdings has advanced its pipeline of antibody therapeutics, securing strategic collaborations and progressing key clinical programs. He has overseen the company's growth and expansion into new markets. Key milestones include the advancement of Batoclimab and Tanfanercept through clinical trials. He has focused on building a strong team and fostering a culture of innovation within the company.
HBMHF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that HBMHF may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB, or for listing on major exchanges like the NYSE or NASDAQ. Companies on this tier may have limited reporting requirements, which can lead to less transparency for investors. Unlike NYSE/NASDAQ listings that demand stringent financial reporting and governance standards, OTC Other companies face fewer requirements, potentially increasing investment risk.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity compared to exchange-listed stocks.
- Potential for wider bid-ask spreads.
- Increased volatility due to less regulatory oversight.
- Higher risk of fraud or manipulation compared to major exchanges.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's regulatory filings and compliance history.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Focus on antibody therapeutics for immunology and oncology.
- Strategic collaborations with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc.
- Pipeline includes Batoclimab and Tanfanercept.
- Operates in Mainland China, the United States, Europe, and internationally.
- Experienced CEO Jingsong Wang.
HBM Holdings Limited Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for HBMHF?
HBM Holdings Limited (HBMHF) currently holds an AI score of 53/100, indicating moderate score. Key strength: Diverse pipeline of antibody therapeutics.. Primary risk to monitor: Potential: Clinical trial failures for pipeline assets.. This is not financial advice.
How frequently does HBMHF data refresh on this page?
HBMHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HBMHF's recent stock price performance?
Recent price movement in HBM Holdings Limited (HBMHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse pipeline of antibody therapeutics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HBMHF overvalued or undervalued right now?
Determining whether HBM Holdings Limited (HBMHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HBMHF?
Before investing in HBM Holdings Limited (HBMHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HBMHF to a portfolio?
Potential reasons to consider HBM Holdings Limited (HBMHF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diverse pipeline of antibody therapeutics.. Additionally: Strategic collaborations with established companies.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of HBMHF?
Yes, most major brokerages offer fractional shares of HBM Holdings Limited (HBMHF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HBMHF's earnings and financial reports?
HBM Holdings Limited (HBMHF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for HBMHF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- OTC market data may have limited reliability.
- AI analysis pending may provide additional insights.